Literature DB >> 23946628

Biosimilars: part 2: potential concerns and challenges for p&t committees.

C Lee Ventola.   

Abstract

P&T committee members need a lot more information before they can evaluate the efficacy and safety, interchangeability, and cost-effectiveness of biosimilar products for inclusion on formularies.

Entities:  

Year:  2013        PMID： 23946628      PMCID： PMC3737987     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  14 in total

Review 1.  Biosimilars and market access: a question of comparability and costs?

Authors:  Steven Simoens; Gilbert Verbeken; Isabelle Huys
Journal:  Target Oncol       Date:  2012-01-17       Impact factor: 4.493

Review 2.  Comparability and biosimilarity: considerations for the healthcare provider.

Authors:  Jaymi F Lee; Jason B Litten; Gustavo Grampp
Journal:  Curr Med Res Opin       Date:  2012-06-06       Impact factor: 2.580

3.  Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.

Authors:  Erwin A Blackstone; Joseph P Fuhr
Journal:  Biotechnol Healthc       Date:  2012

4.  The state of the art in the development of biosimilars.

Authors:  Mark McCamish; Gillian Woollett
Journal:  Clin Pharmacol Ther       Date:  2012-02-08       Impact factor: 6.875

5.  Challenges in the anticipation of biosimilars: how must a P&T committee gear up?

Authors:  Celynda Tadlock
Journal:  Manag Care Interface       Date:  2007-04

6.  Biosimilars: are they ready for primetime in the United States?

Authors:  Bradford R Hirsch; Gary H Lyman
Journal:  J Natl Compr Canc Netw       Date:  2011-08-01       Impact factor: 11.908

7.  President obama reopens debate on patented biologics: will the FDA quickly define an abbreviated pathway for biosimilars?

Authors:  Stephen Barlas
Journal:  P T       Date:  2011-04

8.  FDA Readies New Guidance and User Fee Program for Biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task?

Authors:  Stephen Barlas
Journal:  Biotechnol Healthc       Date:  2012

9.  Biosimilars might not measure up to health plan expectations.

Authors:  Tom Reinke
Journal:  Manag Care       Date:  2012-10

10.  Biosimilars: company strategies to capture value from the biologics market.

Authors:  Bruno Calo-Fernández; Juan Leonardo Martínez-Hurtado
Journal:  Pharmaceuticals (Basel)       Date:  2012-12-12
View more
  6 in total

1.  What Is Your Institution's Position Going To Be on Biosimilars?

Authors:  Danial E Baker
Journal:  Hosp Pharm       Date:  2015-06

Review 2.  Biosimilars in IBD: from theory to practice.

Authors:  Silvio Danese; Stefanos Bonovas; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

3.  Effect on Patients' Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization.

Authors:  Jennifer Fenna; Micheal Guirguis; Caroline Ibrahim; Neeta Shirvaikar; Irwindeep Sandhu; Sunita Ghosh; Melissa Jenkins
Journal:  Can J Hosp Pharm       Date:  2021-04-01

4.  Biosimilars: new promise for reducing healthcare costs.

Authors:  Julia Munsch
Journal:  J Biomed Res       Date:  2014-03-20

5.  Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.

Authors:  Stephen R Chapman; Raymond W Fitzpatrick; Mohammed I Aladul
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

6.  An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.

Authors:  Stanley Cohen; Jose L Pablos; Karel Pavelka; Gerard Anton Müller; Alan Matsumoto; Alan Kivitz; Hui Wang; Eswar Krishnan
Journal:  Arthritis Res Ther       Date:  2019-03-29       Impact factor: 5.156
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.